Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Meagan P., Forleo-Neto, Eduardo, Musser, Bret J., Isa, Flonza, Chan, Kuo-Chen, Sarkar, Neena, Bar, Katharine J., Barnabas, Ruanne V., Barouch, Dan H., Cohen, Myron S., Hurt, Christopher B., Burwen, Dale R., Marovich, Mary A., Hou, Peijie, Heirman, Ingeborg, Davis, John D., Turner, Kenneth C., Ramesh, Divya, Mahmood, Adnan, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Purcell, Lisa A., Baum, Alina, Kyratsous, Christos A., Krainson, James, Perez-Perez, Richard, Mohseni, Rizwana, Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D., Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362593/
https://www.ncbi.nlm.nih.gov/pubmed/34347950
http://dx.doi.org/10.1056/NEJMoa2109682

Ejemplares similares

Ejemplares similares